Cancer News: Lung
The drug Alectinib (Alecensa) received approval by the FDA for the treatment of patients with advanced, metastatic, ALK-positive non-small cell lung cancer.
US regulators approved the monoclonal antibody necitumumab Portrazza as a first-line treatment for advanced squamous non-small cell lung cancer.
U.S. regulators approved osimertinib for the treatment of metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer.
A new study revealed the effectiveness and the safety profile of surgical lung resection for high-risk patients with early stage lung cancer.
The agent everolimus showed real promise in treating patients with nonfunctional neuroendocrine tumors of lung or gastrointestinal origin, a new study reveals.
Non-small cell lung cancer patients who received intensity modulated radiation therapy had lower occurrence of severe pneumonitis, a secondary analysis reported.
Patients with lung cancer patients survived longer if their management included a follow-up program based on computer tomography (CT) of the chest, a new study shows.
U.S. regulators approved nivolumab for the treatment of patients with non-squamous non-small cell lung cancer.
The breakthrough immunotherapy Keytruda got approved by the U.S. FDA to treat patients with advanced non-small cell lung cancer.
Roche’s new immune-system boosting drug, atezolizumab, improved patient outcomes for lung and bladder cancer patients, according to separate phase 2 trials.
A randomized trials showed that the added to chemotherapy inhibitor cetuximab failed to improve survival in patients with advanced non-small cell lung cancer.
Combining traditional chemotherapy with immunotherapy is safe for patients with advanced small cell lung cancer and non-small cell lung cancer, a new study reveals.
Two immunotherapies, Opdivo and Yervoy can be safely and effectively combined to treat patients with previously untreated lung cancer, an early-stage study shows.
The American Society of Clinical Oncology created a guideline to help doctors choose the best therapies for patients with advanced non-small cell lung cancer.
Gefitinib has been approved in the US for the treatment of metastatic non-small cell lung cancer patients with specific tumor characteristics.
AstraZeneca’s lung cancer drug, Iressa has been given the green light from US regulators, as a first-line treatment for lung cancer.
Combining chemotherapy, radiation therapy and surgical removal of the lung may be beneficial for metastatic non-small cell lung cancer patients, a new study proposes.
The immunotherapy nivolumab PD-1 found to be an effective treatment option for patients with non-squamous, non-small cell lung cancer (NSCLC) in a phase 3 trial.
The European regulators have approved Novartis’s drug Zykadia, a treatment for lung cancer patients with a rare genetic mutation.
Patients with gastrointestinal stromal tumors may develop additional malignancies before and after their diagnosis, according to the first population-based study.
Lung cancer patients who used statins in the year prior to or after a lung cancer diagnosis had lower mortality risk, researchers report.
Scientists at a large medical conference discussed the risk of pulmonary embolism and deep vein thrombosis in lung cancer patients after their surgery.
A large prospective study of lung cancer found that oral contraceptives and hormone therapy use are not associated with risk of lung cancer.
A new study of the immunotherapy drug, pembrolizumab, showed safe and favorable durable outcomes to patients with advanced, non-small cell lung cancer.
The drug AZD9291 showed significant antitumor efficacy as it delayed the progression of the disease in non-small cell lung cancer patients.
Lung cancer patients reduced symptoms, increased exercise tolerance and improved quality of life through physical activity.
The FDA approved the drug Opdivo for the treatment of patients with advanced non-small cell lung cancer with progression on/after platinum-based chemotherapy.
Novartis’ treatment for lung cancer, Zykadia, got recommendation for approval from European health regulators.
New research illustrates the high value of PET/CT scans for lung cancer patients, based on how much they can help clinical assessment and management of patients.
A gene mutation, previously related with early-onset Parkinson's disease, was found to be associated with lung cancer.